Paper 106 - SAFETY, EFFICACY, AND PATIENT-REPORTED OUTCOMES WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED PRIOR ANTI-COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 STUDY

Author(s)

• AW

  Andrew J. Wagner, MD, PhD

  MD, PhD
  Dana-Farber Cancer Institute
  Boston, Massachusetts, United States

  Slides

Co-Author(s)

• GD

  Gina D’Amato, MD

  Sylvester Comprehensive Cancer Center, University of Miami
  Miami, Florida, United States
• KG

  Kristen N. Ganjoo, MD

  Stanford Comprehensive Cancer Center
  Palo Alto, California, United States
• SS

  Silvia Stacchiotti, MD

  Medical Oncologist
  Fondazione IRCCS Istituto Nazionale dei Tumori
  Milan, Lombardia, Italy
• HG

  Hans Gelderblom, MD, PhD

  Leiden University Medical Center
  Leiden, Zuid-Holland, Netherlands
• CR

  Christopher W. Ryan, MD

  OHSU Knight Cancer Institute
  Portland, Oregon, United States
• 

  Emanuela Palmerini, MD, PhD

  Consultant Medical oncologist
  IRCCS Istituto Ortopedico Rizzoli
  Bologna, Emilia-Romagna, Italy
• VR

  Vinod Ravi, MD, MBA

  The University of Texas MD Anderson Cancer Center
  Houston, Texas, United States
• RS

  Ramy Saleh, MD

  McGill University Health Centre Research Institute
  Montreal, Quebec, Canada
• AL

  Axel Le Cesne, MD

  Gustave Roussy
  Villejuif, Rhone-Alpes, France
• NB

  Nicholas M. Bernthal, MD

  University of California Los Angeles
  Los Angeles, California, United States
• 

  Michiel AJ van de Sande, Professor (he/him/his)

  Professor in Orthopedic Oncology
  Princes Maxima Center for pediatric oncology and LUMC leiden
  Utrecht / Leiden, Zuid-Holland, Netherlands
• 

  Supraja Narasimhan, PhD (she/her/hers)

  Associate Director, Clinical Scientist
  Deciphera Pharmaceuticals, A member of ONO Pharma
  Waltham, Massachusetts, United States
• BH

  Brooke Harrow, PhD

  Deciphera Pharmaceuticals, LLC
  Waltham, Massachusetts, United States
• AS

  Amanda Saunders, DO

  Deciphera Pharmaceuticals, LLC
  Waltham, Massachusetts, United States
• RR

  Rodrigo Ruiz-Soto, MD

  Deciphera Pharmaceuticals, LLC
  Waltham, Massachusetts, United States
• MS

  Matthew L. Sherman, MD

  Deciphera Pharmaceuticals, LLC
  Waltham, Massachusetts, United States
• WT

  William D. Tap, MD

  Department of Medicine, Memorial Sloan Kettering Cancer Center Department of Medicine, Weill Cornell Medical College
  New York, New York, United States